insert therapeutics unidym tego bio sciences science research anti-cancer drugs RNAi therapeutics carbon-based electronics nanotechnology arrowhead pasadena california nasdaq arwr nanotechnology arrowhead pasadena california nasdaq arwr

Arrowhead Select Financial Data

Revenue
Third quarter of fiscal year 2009, ended June 30, 2009 $2.6M
Nine months ended June 30, 2009 $3.6M

GAAP Consolidated Net Loss
Third quarter of fiscal year 2009, ended June 30, 2009 ($2.5M)
Nine months ended June 30, 2009 ($15.8M)

GAAP EPS (Undiluted)
Third quarter of fiscal year 2009, ended June 30, 2009 ($0.06)
Nine months ended June 30, 2009 ($0.37)


Recent Price (8/12/09) $0.43

Shares Outstanding (8/10/09) 55.4 million

Market Cap $23.8 million